- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02915315
Salt-sensitive Hypertension Study in Lantian County (SHSL)
23. Februar 2017 aktualisiert von: First Affiliated Hospital Xi'an Jiaotong University
Genetics Study of Salt-Sensitive Hypertension in a Chinese Population
Essential hypertension is a complex trait which results from interaction between environmental factors and genetic factors.
Our study aimed to detect the differential expression of LncRNAs and epigenetic changes such as DNA methylation associated with salt sensitive hypertension in human based on a chronic salt loading study conducted in Lantian county, China.
Firstly, a chronic salt loading study will be conducted in a Chinese population to differentiate salt-sensitive and salt-resistant individuals.
Second, LncRNAs and DNA methylation Chip analysis will be performed using samples collected from salt-sensitive and salt resistant individual, and the results will be analyzed by modern bioinformatics methods to seek for differential genetic markers.
In addition, the investigators also try to examine the effects of chronic salt loading on BP, ambulatory BP, microalbuminuria and baPWV and other biochemical indexes.
This project had great significance to reveal molecular genetics mechanism in the development of salt, salt-sensitive and hypertension.
Studienübersicht
Detaillierte Beschreibung
The main contents include: (1) Questionnaire design: questionnaire is designed according to the research contents and purposes.
The standard questionnaires will be used to collect the general information, dietary habits, lifestyle, medical history and family history etc.(2)Anthropometric measurements: blood pressure, height, body weight, waist and hip, pulse will be acquired by medical practitioners who received professional trainings based on World Health Organization (WHO) standards, and passed relevant examinations.(3)
Dietary intervention: The dietary intervention comprise a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt or 51.3mmol of sodium per day) and a high-salt diet for 7 days (18g of salt or 307.8mmol of sodium per day).
During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 21-day study duration.
To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period.
All foods are cooked without salt.
Onsite study staff members add prepackaged salt to the meals of individual subjects as indicated by the study protocol.
(4) Blood and urine samples collection: morning fasting blood, nocturnal enuresis, and 24-hour urine specimen will be collected by medical staffs, and blind tubes will be set up according to 5% of the total samples.
Blood biochemistries including serum total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, fasting glucose, creatinine and hsCRP can be measured using automatic biochemical analyzer.
The sodium and potassium concentrations in the urine will be measured by flame photometry.
The total sodium and potassium excretions in urine in 24h were calculated by multiplying the concentration and 24-h volume of urine.
(5) DNA methylation and LncRNA detection: Using a method of modifying a hydrogen sulfite salt and gene chip technology to detect DNA methylation and LncRNA.
(6) LncRNA: LncRNA will be measured with gene chip technology after the high salt intervention period.
(7) Auxiliary examinations: Auxiliary examinations including carotid intima-media thickness, endothelium-dependent vasodilation (FMD), measurements of brachial-ankle pulse wave velocity (baPWV) and electrocardiographic parameters.
The measurement will be done in hospitals by medical practitioners who received professional trainings and passed relevant examinations.
(8) Data processing and statistics: the investigators should input the data to the database, and utilize software such as SPSS, STATA, Haploview and FBAT to analyze.
(9)Quality control: ① Questionnaire is strictly designed and amended by epidemiologist and clinical experts.
② A standardized "Investigator Handbook" will be stipulated according to the guidelines.
③ Staff members are required to do a rigorous training and pass the exam.
④ The investigation process will be strictly supervised by the principal investigator.
⑤ Data entry use the parallel double entry method.
⑥ During laboratory testing, blank control and blind detection are applied to ensure the quality.
⑦Data analysis is performed by 2-3 postgraduates, inconsistent data need to be double checked.
Studientyp
Beobachtungs
Einschreibung (Voraussichtlich)
70
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Probenahmeverfahren
Wahrscheinlichkeitsstichprobe
Studienpopulation
The study population is ready to recruit from Shaanxi Lantian County, aged 18-65 years old and sex is not limited.
The exclusion criteria were hypertension, use of antihypertensive medication, clinical cardiovascular disease, chronic liver disease, chronic kidney disease, or diabetes mellitus, pregnancy, or high alcohol consumption.
Beschreibung
Inclusion Criteria:
- Han individuals in rural northern China
- adults aged 18-65 years
- individuals who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications were identified as the proband
- the probands'parents,siblings, spouses, and offspring were recruited for the study.
Exclusion Criteria:
- Secondary hypertension
- a history of severe cardiovascular disease
- chronic kidney disease or liver disease
- unable to complete the examination
- unable/refuse to sign the informed consent form
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Baseline survey period
All subjects will continue a normal diet for 3 days in which questionnaire design and anthropometric measurements will be implemented.
|
|
|
Low-salt diet
All subjects will be instructed to maintain a low-salt diet for 7 days (3g of salt or 51.3mmol of sodium per day).
|
The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day).
During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration.
To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period.
All foods are cooked without salt.
Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
Andere Namen:
|
|
High -salt diet
After washout period, all subjects will be instructed to maintain a 18g of salt or 307.8mmol of sodium per day.
|
The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day).
During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration.
To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period.
All foods are cooked without salt.
Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
blood pressure value(mmHg)
Zeitfenster: The first day of the three-day baseline survey period.
|
The study will last approximately 3 months (Oct 2016 to Dec 2016).
During this period, each subject will receive a three-day baseline survey examination.
Three BPs (mmHg) measurement will be obtained using a Blood Pressure Monitor on the first day of the three-day baseline survey period.
|
The first day of the three-day baseline survey period.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Ambulatory Blood Pressure Monitoring(mmHg)
Zeitfenster: Second day of the three-day baseline survey period
|
The study will last approximately 3 months (Oct 2016 to Dec 2016).
During this period, each subject will receive a three-day baseline survey examination.
Ambulatory blood pressure(mmHg)will be measured with Omron Ambulatory Blood Pressure Monitor during the three-day baseline survey period
|
Second day of the three-day baseline survey period
|
|
Microalbuminuria(mg/24h)
Zeitfenster: Second day of the three-day baseline survey period
|
The study will last approximately 3 months (Oct 2016 to Dec 2016).
During this period, each subject will receive a three-day baseline survey examination.
On the second day, 24-hour urinary will be collected and the concentrations of microalbuminuria in the urine sample will be measured with Hitachi biochemical analyzer.
The 24-h microalbuminuria(mg/24h)of each subject is calculated as the concentration of microalbuminuria multiplied by the 24-h urine volume of each individual.
|
Second day of the three-day baseline survey period
|
|
Increased arterial stiffness(baPWV,mm/s)
Zeitfenster: Second day of the three-day baseline survey period
|
The study will last approximately 3 months (Oct 2016 to Dec 2016).
During this period, each subject will receive a three-day baseline survey examination.
Brachial-ankle pulse wave velocity(baPWV, mm/s)will be measured with Noninvasive automatic waveform analyzer during the three-day baseline survey period.
|
Second day of the three-day baseline survey period
|
|
DNA methylation
Zeitfenster: Last day of the low salt or high salt intervention period
|
The study will last approximately 3 months (Oct 2016 to Dec 2016).
During this period, each subject will receive a seven-day high salt intervention subsequent to a seven-day low salt intervention.
DNA methylation will be measured with a method of modifying a hydrogen sulfite salt at the last day of the low salt or high salt intervention.
|
Last day of the low salt or high salt intervention period
|
|
LncRNA
Zeitfenster: Last day of the low salt or high salt intervention period
|
The study will last approximately 3 months (Oct 2016 to Dec 2016).
During this period, each subject will receive a seven-day high salt intervention subsequent to a seven-day low salt intervention.
IncRNA will be measured with gene chip technology at the last day of the low salt or high salt intervention.
|
Last day of the low salt or high salt intervention period
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Hauptermittler: Jianjun Mu, doctor, First Affiliated Hospital Xi'an Jiaotong University
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Mu J, Zheng S, Lian Q, Liu F, Liu Z. Evolution of blood pressure from adolescents to youth in salt sensitivies: a 18-year follow-up study in Hanzhong children cohort. Nutr J. 2012 Sep 14;11:70. doi: 10.1186/1475-2891-11-70.
- Liu F, Zheng S, Mu J, Chu C, Wang L, Wang Y, Xiao H, Wang D, Cao Y, Ren K, Liu E, Yuan Z. Common variation in with no-lysine kinase 1 (WNK1) and blood pressure responses to dietary sodium or potassium interventions- family-based association study. Circ J. 2013;77(1):169-74. doi: 10.1253/circj.cj-12-0900. Epub 2012 Oct 12.
- Wang Y, Liu FQ, Wang D, Mu JJ, Ren KY, Guo TS, Chu C, Wang L, Geng LK, Yuan ZY. Effect of salt intake and potassium supplementation on serum renalase levels in Chinese adults: a randomized trial. Medicine (Baltimore). 2014 Jul;93(6):e44. doi: 10.1097/MD.0000000000000044.
- Wang Y, Jia H, Gao WH, Zou T, Yao S, Du MF, Zhang XY, Chu C, Liao YY, Chen C, Wang D, Ma Q, Hu JW, Wang KK, Yan Y, Sun Y, Hu GL, Niu ZJ, Zhou HW, Zhang X, Wang X, Li CH, Chen FY, Gao K, Zhang J, Guan YJ, Chang J, Yang TL, Mu JJ. Associations of plasma PAPP-A2 and genetic variations with salt sensitivity, blood pressure changes and hypertension incidence in Chinese adults. J Hypertens. 2021 Sep 1;39(9):1817-1825. doi: 10.1097/HJH.0000000000002846.
- Zhang J, Yin Y, Chen L, Chu C, Wang Y, Lv Y, He M, Martin M, Huang PH, Mu JJ, Shyy JY, Yuan ZY. Short-Term High-Salt Diet Increases Corin Level to Regulate the Salt-Water Balance in Humans and Rodents. Am J Hypertens. 2018 Jan 12;31(2):253-260. doi: 10.1093/ajh/hpx148.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Voraussichtlich)
28. Februar 2017
Primärer Abschluss (Voraussichtlich)
1. März 2017
Studienabschluss (Voraussichtlich)
1. März 2017
Studienanmeldedaten
Zuerst eingereicht
21. September 2016
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
22. September 2016
Zuerst gepostet (Schätzen)
27. September 2016
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
27. Februar 2017
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
23. Februar 2017
Zuletzt verifiziert
1. September 2016
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- NSFC(81570381)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .